Introduction. Acute kidney injury (AKI) is a major complication in patients with sepsis and is an independent predictor of mortality. However, the optimal intensity of renal replacement therapy for such patients is still controversial. Methods. From 1 January 2004 to 30 September 2009, we randomly assigned 280 patients with sepsis and AKI to continuous renal replacement therapy by high-volume hemofiltration (50 mL/kg/h, HVHF) or extra high-volume hemofiltration (85 mL/kg/h, EHVHF). The primary study outcome was death from any cause within 28, 60 and 90 days. Results were analyzed by univariate and multivariate methods and by Kaplan-Meier survival curves. Results. A total of 141 patients were given EHVHF and 139 were given HVHF. The two groups had similar baseline characteristics and received treatment for an average of 9.38 days (EHVHF group) and 8.88 days (HVHF group). There were no significant differences between the groups in number of deaths at 28, 60 or 90 days. There were also no differences between the groups in renal outcome of survivors at 90 days. Multivariate analysis indicated that inotropic support by norepinephrine, time in hospital of >7 days, blood platelet count <8 3 10 9 /L, Acute Physiological and Chronic Health Evaluation (APACHE) II score >25, total bilirubin >100 lmol/L, prothrombin time >18 s, serum creatinine <250 lmol/L and blood urea nitrogen >20 mmol/L were independent risk factors for death at 90 days after initiation of renal replacement therapy. Conclusions. In patients with sepsis and AKI, increasing the intensity of renal replacement therapy from 50 (HVHF) to 85 mL/kg/h (EHVHF) had no effect on survival at 28 and 90 days.
Introduction
Sepsis is the leading cause of death in non-coronary intensive care units (ICU) and is currently a major medical challenge [1, 2] . Acute kidney injury (AKI) is a serious complication in patients with sepsis and is usually associated with multi-organ dysfunction syndrome (MODS), a condition characterized by simultaneous renal, cardiovascular and pulmonary dysfunction, and an independent predictor of mortality. Since 1984, increasing evidence has indicated that continuous renal replacement therapy (CRRT) in AKI patients can control azotemia and fluid balance and also remove mediators of sepsis from circulation [3] [4] [5] .
Animal studies of this condition, in which animals were given endotoxin-induced shock and then high-volume hemofiltration (HVHF), indicated that HVHF had beneficial effects on physiological endpoints and survival time [6] [7] [8] .
Clinical studies have shown that increasing doses of hemofiltration were associated with better patient outcome [9, 10] . In other words, patients with sepsis may benefit from the use of more intensive renal filtration. However, there is controversy regarding the clinical benefits of HVHF [11] and the optimal intensity or dose of renal replacement therapy in patients with sepsis and AKI.
We conducted a single center randomized controlled study of patients with sepsis and AKI to examine the effect of CRRT intensity on the survival of patients at 28 and 90 days.
Materials and methods
This study was a prospective, randomized, controlled single-center trial that assessed two levels of CRRT in patients with sepsis and AKI who were admitted to our intensive care unit. The HVHF group was given filtration at a rate of 50 mL/kg/h and the extra high-volume hemofiltration (EHVHF) group was given filtration at a rate of 85 mL/kg/h. The study was conducted between 1 January 2004 and 30 September 2009 in the ICU of the First Affiliated Hospital, College of Medicine, Zhejiang University (Hangzhou, Zhejiang, People's Republic of China). Patient randomization was generated from a computer-generated sequence of random numbers.
The study protocol was approved by the Ethics Committee of the First Affiliated Hospital (College of Medicine, Zhejiang University) and written informed consent was obtained from the patient or from family members before enrollment.
Patients
All 280 enrolled patients were >18 years, suffered from severe sepsis and AKI in the ICU, required CRRT and met at least one of the following criteria: oliguria (urine output <100 mL in a 6-h period and unresponsive to fluid resuscitation), serum potassium concentration >6.5 mmol/L, severe acidemia (pH < 7.2), serum creatinine (SCr) >250 lmol/L or presence of severe organ edema (e.g. pulmonary edema). The diagnosis of septic shock was referenced to the criteria [12, 13] . Exclusion criteria were presence of a malignant tumor, chronic renal insufficiency (SCr > 133 lmol/L) or receiving any kind of renal replacement therapy before randomization.
Renal replacement therapy
All patients in both groups were treated with continuous venous hemofiltration (CVVH). Replacement fluid was delivered into the extracorporeal circuit at a pre-dilution/post-dilution ratio of 2/1. The replacement fluid was based on patient body weight at the time of randomization and was 50 mL/kg/h (HVHF group) or 85 mL/kg/h (EHVHF group). Central venous access was used and the catheters of 11.5 or 13.5 FR 3 16 cm, 11.5 or 13.5 FR 3 19.5 cm (Kendall, Tyco healthcare Group LP, Mansfield, MA) were utilized. Blood flow was kept >250 mL/min. Polysulfone filters (AV600; Fresenius Medical Care, Bad Homburg, Germany) were used for all patients and the filter was changed when the transmembrane pressure of the filter was >250 mmHg.. AK-ultra 200 (Gambro, Lund, Sweden) online replacements (bicarbonate solution) were used as the replacement fluid and were infused into the CRRT circuit instantly whenever it was produced. Figure 1 shows how the CRRT replacement fluid was generated. Replacement fluid was heated to 37-39°C based on patients' temperature. When patients' temperature decreased <36°C, warming and heating measures were increased. An ACCURA (Baxter, McGaw Park, IL) was used as the CRRT machine. Anti-coagulation was performed according to patient condition, either with unfractionated heparin, low molecular weight heparin or heparin-free anti-coagulation. In the first 3 days, 85 mL/kg/h were applied in all patients from the EHVHF group and 50 mL/kg/h in all patients from the HVHF group. After 3 days, if the renal support needed to be continued, the same dose was adopted.
Dosing of antibiotics and nutrition of all patients were adjusted according to clearance of CRRT during the CRRT period.
Outcomes
The primary study outcome was death from any cause within 28, 60 and 90 days after randomization. Secondary outcomes were length of stay in the ICU and hospital and renal outcome of survivors at 90 days after randomization. Norepinephrine dose, PaO 2 /FiO 2 ratio and body temperature were observed pre and 24 h post CRRT in the two groups. Related risk factors for death at 90 days after initiation of renal replacement therapy of all patients were analyzed.
Statistical analysis
All data are presented as means AE standard deviations. Categorical parameters were compared by a v 2 test and continuous variables were compared by a ttest and the Mann-Whitney U-test. Patient survival was analyzed by the Kaplan-Meier method and compared by the log-rank test. The Cox proportional hazard survival model was used to identify prognostic factors associated with survival time at 90 days after initiation of renal replacement therapy. When constructing the Cox multivariate model, univariate factors with Pvalues <0.2 were used. Statistical analysis was performed with SPSS 11.5 (SPSS Inc, Chicago, IL). A P-value <0.05 was considered significant. study. One hundred and forty-one patients were randomly assigned to the EHVHF group and 139 patients to the HVHF group. All initial baseline characteristics were similar in the two groups (Table 1) . A total of 51.06% of patients in the EHVHF group and49.64% of patients in the HVHF group had septic shock. A total of 35.5% of patients in the EHVHF group and 43.2% of patients in the HVHF group were receiving norepinephrine. The initial SCr concentrations in the EHVHF group and HVHF group were 248.1 and 262.9 lmol/L, respectively. Before randomization, patients in the EHVHF group stayed an average of 5.4 days in the ICU and 9.33 days in the hospital; patients in the HVHF group stayed an average of 6.18 days in the ICU and 13.83 days in the hospital.
Results

Between
The actual flow rate of effluent was 87.54 mL/kg/h in the EHVHF group and 49.99 mL/kg/h in the HVHF group. The mean duration of renal replacement therapy was similar for the two groups (9.38 versus 8.88 days) ( Table 2) .
At 28 days after randomization, 81 EHVHF patients (57.4%) and 81 HVHF patients (58.3%) died. At 60 days after randomization, 84 EHVHF patients (59.6%) and 87 HVHF patients (62.6%) died. At 90 days after Effect of the intensity of CRRT in patientsrandomization, 84 EHVHF patients (59.6%) and 88 HVHF patients (63.3%) died (Table 2) . Kaplan-Meier analysis indicated that the two groups had similar probability of survival for 90 days (P ¼ 0.58, Figure 2) . A subgroup analysis of septic shock patients also showed that increasing the intensity of renal replacement therapy had no effect on survival at 28 days (EHVHF versus HVHF: 30.6 versus 29.0%), 60 days (27.8 versus 24.6%) and 90 days(27.8 versus 24.6%).
There were also no significant differences between the groups in any other outcomes (Table 2 ). In particular, after randomization, there were no significant differences in length of stay in the ICU (21.9 days for the EHVHF group, 25.9 days for the HVHF group, P ¼ 0.62), length of stay in the hospital (35.5 days for the EHVHF group, 38.5 days for the HVHF group, P ¼ 0.67) or renal outcome of survivors at 90 days. At 90 days, there were four EHVHF patients (7.0% of survivors) and five HVHF patients (9.6% of survivors) dependent on renal replacement therapy. There was also no significant difference in mean SCr of survivors at discharge (EHVHF, 100.2 AE 74.2 lmol/L versus HVHF, 106.3 AE 93.3 lmol/L; P ¼ 0.71).
There was no difference of norepinephrine dose pre-and 24 h post-CRRT in the EHVHF group (0.35 AE 0.69 lg/ kgÁmin versus 0.38 AE 0.66 lg/kgÁmin, P ¼ 0.901). And there was also no difference of norepinephrine dose in the HVHF group (0.44 AE 0.84 lg/kgÁmin versus 0.61 AE 1.02 lg/kgÁmin, P ¼ 0.465).
There was an increasing trend of PaO 2 /FiO 2 ratio 24 h post-CRRT compared with pre-CRRT in the EHVHF group (246.31 AE 135.43 versus 215.59 AE 108.75, P ¼ 0.06). However, there was no significant difference observed in the HVHF group (229.62 AE 147.65 versus 233.50 AE 110.60, P ¼ 0.82).
Body temperature was observed to be significantly decreased in both groups pre-and 24 h post-treatment (EHVHF, 37.86 AE 1.02°C versus 37.24 AE 0.80°C, P < 0.001; HVHF, 37.59 AE 1.04°C versus 37.21 AE 0.89°C, P ¼ 0.003). Three patients (2.13%) in the EHVHF group and one patient in the HVHF group had a body temperature of <34°C during CRRT (P ¼ 0.622). These four hypothermia patients gradually improved after strengthening warming measure.
Next, we performed a univariate analysis of factors associated with survival at 90 days after initiation of renal replacement therapy, including age, sex, diabetes mellitus, septic shock, mechanical ventilation, use of vasoactive drugs, inotropic support by norepinephrine, time in ICU before randomization, time in hospital before randomization, APACHE II score before randomization, SCr, blood urea nitrogen (BUN), serum albumin (Alb), total bilirubin (TB), prothrombin time (PT), bicarbonate and PaO 2 /FiO 2 before randomization and intensity of CRRT. Univariate factors with P-values <0.2 were entered into the multivariate analysis. The multivariate analysis indicated that inotropic support by norepinephrine, time in hospital of >7 days, blood platelet count <8 3 10 9 /L, APACHE II score >25, TB >100 lmol/L, PT >18 s, SCr <250 lmol/L and BUN >20 mmol/L before randomization were independently associated with increased risk of death at 90 days after initiation of renal replacement therapy (Table 3) .
Discussion
Sepsis is a major unresolved medical challenge and is the leading cause of AKI and a part of MODS, a very serious medical condition. CRRT is an important treatment modality for sepsis because it can extract or lower the concentrations of many mediators of inflammation and because it has immunomodulatory effects [14, 15] . The removal of inflammatory agents by CRRT can be enhanced by increasing CRRT intensity by using a membrane with higher permeability [16] or by the combined use of adsorption techniques [17, 18] . Previous animal studies and clinical studies have demonstrated Fig. 2 . Kaplan-Meier estimates the probability of survival at 90 days of patients with sepsis and AKI who were given HVHF or EHVHF (P ¼ 0.58). that CRRT treatment dose was correlated with outcome. For example, Ronco et al. [9] reported a decrease in mortality from 75 to 53% when CRRT increased from 20 to 45 mL/kg/h in patients with sepsis. Ratanarat et al. [19] demonstrated that pulse HVHF (85-100 mL/kg/h for 6-8 h, followed by 35 mL/kg/h for 16-18 h) significantly reduced apoptotic plasma activity, the need for vasopressor and 28-day mortality in responders. In contrast to these previous studies, our single center randomized controlled trial of the effect of CRRT intensity in patients with sepsis and AKI indicated that 50 and 85 mL/ kg/h CRRT were associated with similar mortality rates. There were also no significant differences between our two groups in treatment time, rate of renal recovery and time in the ICU or hospital. The HVHF dose in our trial (50 mL/kg/ h) was very similar to that used by Ronco et al. [9] (45 mL/ kg/h) and we also had similar mortality rates (50% in the Ronco et al. study and 55.17% in our study). For the EHVHF dose, we chose a level similar to that used by Ratanarat et al. [19] . However, Ratanarat et al. implemented extra highvolume filtration for 6-8 h, followed by treatment at 35 mL/kg/h for 16-18 h; we used continuous extra high-volume filtration of 85 mL/kg/h for at least 3 days.
However, our results are in accordance with some recent studies. In the ATN study [20] , 1124 critically ill patients with AKI were enrolled. In their study, hemodynamically stable patients underwent intermittent hemodialysis and hemodynamically unstable patients underwent CVVH. The intensive treatment strategy of CVVH was 35 mL/kg/h and the less intensive treatment strategy was 20 mL/kg/h. Their results showed that the rate of death from any cause by Day 60 was not different between the two groups. And the recovery of kidney function or the rate of non-metal organ failure was also not different between the two groups. Payen's [21] multi-center study assessed the effect of early application of hemofiltration on the degree of organ dysfunction and plasma cytokine levels in patients with severe sepsis or septic shock. About 76 patients were enrolled and randomized to the hemofiltration group (25 mL/kg/h, continued 96-h period) or the conventionally managed group. The results showed that early application of standard CVVH was deleterious in severe sepsis and septic shock. And there were also no differences detected in plasma cytokine levels. The Randomized Evaluation of Normal versus Augmented Levels of RRT (RENAL) study [22] , also showed that high-intensity and low-intensity treatment were associated with similar mortality rates. In the RENAL study, 747 patients were given highintensity CRRT (40 mL/kg/h) and 761 patients were given low-intensity CRRT (25 mL/kg/h); after 90 days, the mortality in each group was 44.7%. There was also no difference in the mortality rates at 90 days in the subset of patients with sepsis (46.8% for high intensity patients, 51.2% for low intensity patients, P ¼ 0.84). Our study was somewhat different from the above studies, we only enrolled patients with sepsis and AKI and our CRRT intensity was even higher. However, the total trend is consistent.
Two recent meta-analyses also showed the same results. In Van Wert's [23] meta-analysis, 12 trials and 3999 patients were studied. They found no effect of high-dose renal replacement therapy on mortality or dialysis dependence among survivors. In sub-groups analysis, the effect on mortality was also similar in patients with sepsis versus without sepsis. Zhongheng et al. [24] analyzed the effect of intensive-dose CRRT on mortality and other clinical outcomes. Their results also indicate that intensive-dose CRRT had no beneficial effects on clinical outcomes and that there were more complications in the group given an intensive-dose CRRT.
Boussekey et al. [25] showed that HVHF (65 versus 35 mL/kg/h) decreased vasopressor requirement and increased urine output of patients with septic shock and renal failure but had no effect on survival at Day 28. In our study, decrease in vasopressor requirement after 24 h of treatment was not found in EHVHF group and HVHF group. However, we found that there was an increasing trend of PaO 2 /FiO 2 ratio 24 h post-treatment compared with pre-treatment in EHVHF group (P ¼ 0.06) which was not found in the HVHF group.
Late initiation of renal support may have affected he results of our study, although when to initiate intervention is a controversial issue still in debate. In our study, CRRT was started after 5 days from ICU admission (almost 9 days from hospital admission) in the EHVHF group. In the HVHF group, CRRT was initiated after 6 days from ICU admission (13 days from hospital admission). In both groups, the start of CRRT may have come too late to have an effect on the course of the disease, which may explain the high mortality rate seen in our study and is comparable to the ATN study [20] .
The possible adverse effects of higher intensity CRRT such as antibiotics, amino acids and nutrients clearances and hypothermia may counteract the positive effects of increasing CRRT intensity. Increasing CRRT dose will increase many antibiotics [26] [27] [28] , amino acids [29] , watersoluble vitamins [30] and partially micronutrients [31, 32] loss such as selenium, copper, which correlated with the effluent rate of CRRT. Additionally, the incidence of hypophosphatemia was also very high (65.1% in higher intensity CRRT group and 54% in lower intensity CRRT group) [22] . CRRT frequently induces temperature decrease [33, 34] and our study also showed that in both groups, especially in the EHVHF group. Body temperature could play an important role in influencing some cellular functions of human white blood cells and can stimulate polymorphonuclear neutrophils respiratory burst [35] . HVHF will indiscriminately remove both inflammatory and antiinflammatory cytokines. Removal of anti-inflammatory cytokines can have deleterious effects on sepsis patients. So, the possible adverse effects of higher intensity CRRT should be emphasized and further study into the adverse effects of higher intensity CRRT counteracting positive effects of increasing CRRT intensity should be done.
Additionally, we also analyzed independent risk factors for death at 90 days after initiation of renal replacement therapy. We found that in our study, inotropic support by norepinephrine, low platelet count (<8 3 10 9 /L), high APACHE II score (>25), long PT (>18 s) and high TB level (>100 lmol/L) before randomization were independent risk factors for mortality. Similarly, Bagshaw et al. [36] reported that liver disease and high APACHE II scores were independent risk factors for ICU patients at 1 year and Vanderschueren et al. [37] reported that thrombocytopenia was an independent prognostic factor for ICU patients. In our study, results also showed that SCr <250 lmol/L before CRRT was another independent risk factor for mortality and this has also been reported by Jorge's study [38] . Another important observation of the present study is that staying in the hospital for >7 days before randomization was also an independent risk factor for 90-day survival. This indicates that a longer hospital stay before initiation of CRRT is associated with increased mortality in patients with sepsis and AKI. Thus, we suggest that patients with sepsis and AKI should be given CRRT treatment as soon as possible.
Limitations of the study
Our study has several limitations. Firstly, the time of renal support initiation was relatively late which may have had influenced the effectiveness of the CRRT treatment leading to the high mortality rate seen and is one of the major issues. Secondly, we did not include a standard dose group (20-35 mL/kg/h) in our study. Finally, we did not assess all possible side effects of EHVHF. We suggest that a large multi-center prospective randomized controlled trial be carried out, where the intervention initiation time be started earlier, to confirm our findings.
Conclusions
In summary, our study indicates that increasing the intensity of renal replacement therapy from 50 to 85 mL/kg/h in patients with sepsis and AKI does not decrease mortality, improves recovery of kidney function and decrease the time stay in ICU and hospital. These results do not imply that the dose of renal replacement therapy is not important in patients with sepsis and AKI and have no effect if the time of renal support initiation is relatively earlier. Other studies about time of renal support initiation and possible adverse effect of high-intensity CRRT would be necessary to decrease mortality of patients with sepsis and AKI in the further study.
